Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High – Here’s What Happened

Pharvaris N.V. (NASDAQ:PHVS) shares hit a new 52-week high during mid-day trading on Friday . The company traded as high as $31.47 and last traded at $30.8120, with a volume of 27810 shares traded. The stock had previously closed at $29.68.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on PHVS shares. Wedbush raised their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Wall Street Zen lowered Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.73.

Pharvaris Stock Up 1.7%

The company has a market capitalization of $1.97 billion, a PE ratio of -8.95 and a beta of -2.34. The stock has a 50-day moving average of $27.75 and a 200 day moving average of $26.27.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities analysts forecast that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pharvaris news, CEO Berndt Modig sold 23,333 shares of Pharvaris stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42. Following the sale, the chief executive officer directly owned 142,084 shares of the company’s stock, valued at approximately $3,941,410.16. The trade was a 14.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total value of $881,402.40. Following the sale, the director directly owned 355,167 shares in the company, valued at approximately $10,768,663.44. The trade was a 7.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 150,659 shares of company stock worth $4,489,587 in the last quarter. 11.84% of the stock is currently owned by company insiders.

Institutional Trading of Pharvaris

A number of hedge funds have recently made changes to their positions in PHVS. California State Teachers Retirement System raised its stake in Pharvaris by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after buying an additional 520 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris in the 4th quarter worth $35,000. Public Employees Retirement System of Ohio increased its stake in shares of Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.